Immunohistochemical Expression Profiles of Cell Adhesion Molecules, Matrix Metalloproteinases and their Tissue Inhibitors in Central and Peripheral Neoplastic Foci of Feline Mammary Carcinoma

Pisamai, Sirinun; Rungsipipat, Anudep; Kunnasut, Nanthida; Suriyaphol, Gunnaporn

doi:10.1016/j.jcpa.2017.07.004

Cited by 6 publications

(6 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent review article describes that MMPs are present in a variety of animals, including cats [ 38 ]. For example, studies have shown that MMPs are expressed in feline tumors, including MMP9 and MMP2, in feline meningioma and mammary cancer [ 39 , 40 ], and MMP9 in feline lymphoma [ 41 ]. Therefore, it is not surprising that the CD147, as an inducer of MMP activity, would have a role in feline tumors as it does for human cancer.…”

Section: Discussionmentioning

confidence: 99%

CD147 and Cyclooxygenase Expression in Feline Oral Squamous Cell Carcinoma

Nasry

Wang

Jones

et al. 2018

Veterinary Sciences

View full text Add to dashboard Cite

Feline oral squamous cell carcinoma (OSCC) is a highly invasive form of cancer in cats. In human OSCC, cluster of differentiation 147 (CD147) contributes to inflammation and tumor invasiveness. CD147 is a potential therapeutic target, but the expression of CD147 in feline OSCC has not been examined. Immunohistochemistry was used to determine if cyclooxygenase 2 (COX-2) and CD147 expression in feline OSCC biopsies was coordinated. Tumor cells were more likely to express COX-2 (22/43 cases or 51%) compared to stroma (8/43 or 19%) and adjacent oral epithelium (9/31 cases or 29%) (p < 0.05). CD147 was also more likely to occur in tumor cells compared to stroma and adjacent mucosa, with 21/43 (49%) of cases having >50% tumor cells with mild or moderate CD147 expression, compared to 9/28 (32%) in adjacent epithelium and only 5/43 (12%) in adjacent stroma (p < 0.05). In feline OSCC cell lines (SCCF1, SCCF2, and SCCF3), CD147 gene expression was more consistently expressed compared to COX-2, which was 60-fold higher in SCCF2 cells compared to SCCF1 cells (p < 0.05). CD147 expression did not correlate with COX-2 expression and prostaglandin E2 (PGE2) secretion, indicating that they may be independently regulated. CD147 potentially represents a novel therapeutic target for the treatment of feline OSCC and further study of CD147 is warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

CD147 and Cyclooxygenase Expression in Feline Oral Squamous Cell Carcinoma

Nasry

Wang

Jones

et al. 2018

Veterinary Sciences

View full text Add to dashboard Cite

show abstract

“…MMP-2 degraded cell matrix to promote the ability to break through cell basement membrane. TIMP-2, as natural inhibitors of MMP, can affect the combination of MMP-2 and substrate ( 34 ). Therefore, E-cadherin, MMP-2 and TIMP-2 were considered as marked proteins in the process of migration and invasion in many types of cancer.…”

Section: Discussionmentioning

confidence: 99%

Downregulation of RPN2 induces apoptosis and inhibits migration and invasion in colon carcinoma

Jiang

2018

Oncol Rep

View full text Add to dashboard Cite

The morbidity of colorectal cancer (CRC) increases annualy, which accounts to higher mortality worldwide. Therefore, it is important to study the pathogenesis of colon cancer. Ribophorin II (RPN2), part of the N-oligosaccharyltransferase complex, is highly expressed in CRC. In the present study, we investigated whether RPN2 can regulate apoptosis, migration and invasion by RNA interference in CRC and sought to clarify the molecular mechanism involved. Based on previous research, an abnormal high expression of RPN2 was observed in CRC tissues and cell lines by real-time (RT)-PCR, immunohistochemistry (IHC) and western blot analysis. RPN2 knockdown via small RNA interference (siRNA) strategy attenuated the expression of RPN2 at the mRNA and protein levels in vivo, leading to decreased cell viability and increased cell apoptosis. In addition, RNAi-RPN2 effectively arrested the cell cycle at the G0/G1-phase in SW1116 and SW480 cells. Furthermore, the Transwell assay demonstrated that cell migration and invasion abilities were significantly inhibited after cell transfection with RPN2 interference plasmid. The apoptosis-related protein (caspase-3) expression was increased and the cell cycle-related protein (cyclin D1) expression was decreased in the siRNA-RPN2 group. RT-PCR and western blot analysis results indicated that migration- and invasion-related proteins including E-cadherin, matrix metalloproteinases (MMP)-2 and TIMP-2 were markedly regulated by RPN2 siRNA. Phosphorylation levels of signal transducer and activator of transcription (STAT)3 and Janus kinase (JAK)2 were inhibited by RPN2 siRNA. These findings indicated a novel pathway of tumor-promoting activity by RPN2 in CRC, with significant implications for unraveling the tumorigenesis of CRC.

show abstract

“…MMP-2 has been implicated in carcinogenesis and invasive features of various types of cancers [ 8 – 12 ]. In feline mammary carcinoma, the expression of MMP-2 in peripheral neoplastic foci of tumors with high histological grade (grade III) was higher than that in low-grade tumors[ 13 ]. Overexpression of MMP-2 was found in prostate cancer tissue, as compared with benign prostatic hyperplasia tissue, and the level of MMP-2 expression was correlated with clinical stage [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Serum MMP-2 as a potential predictive marker for papillary thyroid carcinoma

Shi

et al. 2018

PLoS ONE

View full text Add to dashboard Cite

ObjectiveThe prevalence of papillary thyroid carcinoma (PTC) is rising rapidly. However, there are no reliable serum biomarkers for PTC. This study aimed to investigate the validity of preoperative serum matrix metalloproteinase-2 (MMP-2) as a biomarker for predicting prognosis of PTC after total or partial thyroidectomy.MethodsMale patients with PTC or a benign thyroid nodule (BTN) and healthy controls (HCs) were retrospectively included. Receiver operating characteristic (ROC) curves were constructed to evaluate the performance of preoperative serum MMP-2 in diagnosing PTC, predicting lymph node metastasis (LNM), and predicting structurally persistent/recurrent disease (SPRD). Multivariate logistic regression and Cox regression were applied to identify independent risk factors for SPRD.ResultsThe preoperative serum MMP-2 concentration in the PTC group was higher than those in BTN and HC groups. The concentration of postoperative serum MMP-2 decreased in comparison with pre-operation. ROC curves showed that serum MMP-2 could differentially diagnose PTC from BTN at the cutoff value of 86.30 ng/ml with an area under the curve (AUC) of 0.905 and could predict central LNM (CLNM) at the cutoff value of 101.55 ng/ml with an AUC of 0.711. Serum MMP-2 ≥101.55 ng/ml, age ≥45 years, and advanced TNM stage were independent risk factors for CLNM. Patients with SPRD had a higher median MMP-2 level (149.22 ng/ml) than patients without SPRD (104.55 ng/ml). Serum MMP-2 at the cutoff value of 144.04 ng/ml could predict SPRD in PTC patients with an AUC of 0.803. Advanced TNM stage and serum MMP-2 ≥144.04 ng/ml were independent risk factors for SPRD. Patients with serum MMP-2 ≥144.04 ng/ml had a worse clinical outcome than those with MMP-2 <144.04 ng/ml.ConclusionPreoperative serum MMP-2 may serve as a biomarker for diagnosing PTC and a predictive indicator for LNM and SPRD in male patients with PTC.

show abstract

Immunohistochemical Expression Profiles of Cell Adhesion Molecules, Matrix Metalloproteinases and their Tissue Inhibitors in Central and Peripheral Neoplastic Foci of Feline Mammary Carcinoma

Cited by 6 publications

References 52 publications

CD147 and Cyclooxygenase Expression in Feline Oral Squamous Cell Carcinoma

CD147 and Cyclooxygenase Expression in Feline Oral Squamous Cell Carcinoma

Downregulation of RPN2 induces apoptosis and inhibits migration and invasion in colon carcinoma

Serum MMP-2 as a potential predictive marker for papillary thyroid carcinoma

Contact Info

Product

Resources

About